Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of Novel Quadruple-Combination Therapy With Preveon (Adefovir Dipivoxil; Bis-POM PMEA), Abacavir (1592U89), Sustiva (Efavirenz; DMP-266), and Amprenavir (141W94) for the Treatment of HIV-1 Infection in Patients Who Have Failed Previous Protease Inhibitor Treatment

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00002419

Enrollment

Registered

2001-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Drug Therapy, Combination, HIV Protease Inhibitors, Reverse Transcriptase Inhibitors, Anti-HIV Agents

Brief summary

The purpose of this study is to see if it is safe and effective to give adefovir dipivoxil plus abacavir (ABC) plus efavirenz (EFV) plus amprenavir (APV) to HIV-infected patients who have failed to respond to previous treatment with protease inhibitors (PIs).

Detailed description

Patients receive a treatment regimen of adefovir dipivoxil, abacavir, efavirenz, and amprenavir for 24 weeks. During the study, patients are evaluated for changes from baseline in plasma HIV-1 RNA levels and lymphocyte subsets and for development of adverse events and toxicities. Patients who experience virologic failure are discontinued from the study. After Week 24, patients with documented virologic response are eligible to continue receiving the study treatment and to attend scheduled follow-up visits.

Interventions

DRUGAbacavir sulfate

DRUGAmprenavir

DRUGEfavirenz

DRUGAdefovir dipivoxil

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

13 Years to No maximum

Healthy volunteers

Inclusion criteria

You may be eligible for this study if you: * Are HIV-positive. * Had an HIV level of at least 2,000 copies/ml after 6 months of treatment with at least 1 PI other than amprenavir (meaning you failed PI treatment). * Are at least 13 years old (need consent of parent or guardian if under 18). * Are able to complete the study. * Agree to use effective barrier methods of birth control, such as condoms, during the study.

Exclusion criteria

You will not be eligible for this study if you: * Have certain serious medical conditions, including AIDS-related cancers (except Kaposi's sarcoma) that require treatment during the study. * Have ever taken or are allergic to adefovir dipivoxil, ABC, APV, EFV. * Are participating in another anti-HIV drug trial during this study. * Have taken certain medications within 30 days prior to study entry, including medications that affect your immune system. * Have been diagnosed with hepatitis within the past 30 days. * Abuse alcohol or drugs. * Are pregnant or breast-feeding. * Have ever taken NNRTIs. * Have ever taken ddI or d4T. * Have received chemotherapy or radiation therapy within 30 days prior to study entry.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026